Discovery illuminates how inflammatory bowel disease promotes colorectal cancer
A chain of immune reactions in the gut—driven by a key signaling protein and a surge of white blood cells from the bone marrow—may help explain why people with inflammatory bowel disease (IBD) have a higher risk of colorectal cancer, according to a preclinical study by Weill Cornell Medicine investigators. The findings point to new possibilities for diagnosis, monitoring and treatment.
The study began with a focus on TL1A, an inflammatory immune signaling protein known to be associated with IBD and colorectal cancer. Experimental drugs that block TL1A activity have shown great promise against IBD in clinical trials, but how the signaling ...